Cyclooxygenase-2: How good is it as a target for cancer chemoprevention?
Open Access
- 30 September 2005
- journal article
- review article
- Published by Elsevier BV in European Journal Of Cancer
- Vol. 41 (13), 1854-1863
- https://doi.org/10.1016/j.ejca.2005.04.013
Abstract
No abstract availableKeywords
This publication has 100 references indexed in Scilit:
- Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention TrialNew England Journal of Medicine, 2005
- Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma PreventionNew England Journal of Medicine, 2005
- Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac SurgeryNew England Journal of Medicine, 2005
- 15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-β-induced suppressor of human gastrointestinal cancersProceedings of the National Academy of Sciences of the United States of America, 2004
- COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situBritish Journal of Cancer, 2004
- Cyclooxygenase-2 Is Overexpressed in HER-2/neu-positive Breast CancerPublished by Elsevier BV ,2002
- Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid ArthritisJama-Journal Of The American Medical Association, 2000
- The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous PolyposisNew England Journal of Medicine, 2000
- Prostaglandin synthase 2Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1996
- Characterization of the Genomic Structure, Chromosomal Location and Promoter of Human Prostaglandin H Synthase-2 GeneBiochemical and Biophysical Research Communications, 1994